NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis $5.94 -0.34 (-5.41%) Closing price 04:00 PM EasternExtended Trading$5.96 +0.02 (+0.35%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Capricor Therapeutics Stock (NASDAQ:CAPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Capricor Therapeutics alerts:Sign Up Key Stats Today's Range$5.68▼$6.3250-Day Range$5.94▼$11.4252-Week Range$3.98▼$23.40Volume2.00 million shsAverage Volume1.34 million shsMarket Capitalization$271.58 millionP/E RatioN/ADividend YieldN/APrice Target$22.56Consensus RatingBuy Company Overview Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms. The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury. Capricor has completed a Phase II trial in DMD that demonstrated potential functional benefits in ambulatory and non-ambulatory patients, and it has initiated follow-on studies to further characterize safety and efficacy. In addition, Capricor’s CAP-2003 program harnesses exosomes derived from CDCs to deliver bioactive molecules that may promote tissue repair, representing a next-generation approach to regenerative medicine. Capricor serves patients throughout the United States and collaborates with academic and clinical research institutions to accelerate the translation of its therapies. The company’s research and development efforts are supported by strategic partnerships that provide access to specialized manufacturing, preclinical models, and clinical trial networks. Capricor’s leadership team is led by President and CEO Linda L. Marbán, PhD, who co-founded the company and has overseen its growth from an early-stage venture to a publicly traded biotech enterprise.AI Generated. May Contain Errors. Read More Capricor Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreCAPR MarketRank™: Capricor Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 542nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCapricor Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Capricor Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Capricor Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.83% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 2.16%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted24.83% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 2.16%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.40 News SentimentCapricor Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Capricor Therapeutics this week, compared to 12 articles on an average week.Search Interest8 people have searched for CAPR on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.50% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPR Stock News HeadlinesCAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 4 at 4:00 PM | globenewswire.comThe Gross Law Firm Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 – CAPRSeptember 4 at 3:42 PM | globenewswire.comMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize. That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works.September 4 at 2:00 AM | American Alternative (Ad)CAPR LAWSUIT ALERT: The Gross Law Firm Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSeptember 4 at 8:45 AM | prnewswire.comCAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud LawsuitSeptember 4 at 5:00 AM | prnewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor TherapeuticsSeptember 3 at 8:39 AM | globenewswire.comCAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the FirmSeptember 3 at 8:10 AM | globenewswire.comCAPR DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CAPRSeptember 2 at 8:29 PM | globenewswire.comSee More Headlines CAPR Stock Analysis - Frequently Asked Questions How have CAPR shares performed this year? Capricor Therapeutics' stock was trading at $13.80 at the beginning of the year. Since then, CAPR shares have decreased by 57.0% and is now trading at $5.94. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics, Inc. (NASDAQ:CAPR) released its earnings results on Monday, August, 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.09. Capricor Therapeutics had a negative net margin of 181.71% and a negative trailing twelve-month return on equity of 62.71%. Read the conference call transcript. Who are Capricor Therapeutics' major shareholders? Capricor Therapeutics' top institutional investors include Geode Capital Management LLC (2.11%), Perceptive Advisors LLC, LMR Partners LLP and Boothbay Fund Management LLC. Insiders that own company stock include Shinyaku Co Ltd Nippon, David B Musket, Paul Gisbert Auwaerter and Xavier Avat. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings8/11/2025Today9/04/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CAPR CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075Employees101Year FoundedN/APrice Target and Rating Average Price Target for Capricor Therapeutics$22.56 High Price Target$30.00 Low Price Target$12.00 Potential Upside/Downside+279.7%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$40.47 million Net Margins-181.71% Pretax Margin-522.48% Return on Equity-62.71% Return on Assets-50.82% Debt Debt-to-Equity RatioN/A Current Ratio4.37 Quick Ratio4.37 Sales & Book Value Annual Sales$22.27 million Price / Sales12.19 Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book1.86Miscellaneous Outstanding Shares45,720,000Free Float40,917,000Market Cap$271.58 million OptionableOptionable Beta0.73 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CAPR) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.